Selectivity and mechanism of action of a growth factor receptor-bound protein 2 Src homology 2 domain binding antagonist

Alessio Giubellino, Zhen Dan Shi, Lisa M. Miller Jenkins, Karen M. Worthy, Lakshman K. Bindu, Gagani Athauda, Benedetta Peruzzi, Robert J. Fisher, Ettore Appella, Terrence R. Burke, Donald P. Bottaro

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

We have shown previously that a potent synthetic antagonist of growth factor receptor-bound protein 2 (Grb2) Src homology 2 (SH2) domain binding (1) blocks growth factor stimulated motility, invasion, and angiogenesis in cultured cell models, as well as tumor metastasis in animals. To characterize the selectivity of 1 for the SH2 domain of Grb2 over other proteins containing similar structural binding motifs, we synthesized a biotinylated derivative (3) that retained high affinity Grb2 SH2 domain binding and potent biological activity. To investigate the selectivity of 1 and 3 for Grb2, the biotinylated antagonist 3 was used to immobilize target proteins from cell extracts for subsequent identification by mass spectrometry. Non-specific binding was identified in parallel using a biotinylated analogue that lacked a single critical binding determinant. The mechanism of action of the antagonist was further characterized by immunoprecipitation, immunoblotting, and light microscopy. This approach to defining protein binding antagonist selectivity and molecular basis of action should be widely applicable in drug development.

Original languageEnglish (US)
Pages (from-to)7459-7468
Number of pages10
JournalJournal of medicinal chemistry
Volume51
Issue number23
DOIs
StatePublished - Dec 11 2008

Bibliographical note

Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Selectivity and mechanism of action of a growth factor receptor-bound protein 2 Src homology 2 domain binding antagonist'. Together they form a unique fingerprint.

Cite this